As part of Green June, the awareness month dedicated to gynecological cancers, we are pleased to present a new video in our series “CARPEM Advances in 5 Minutes”, highlighting recent advances in endometrial cancer research.
This video retraces several years of research led by Guillaume Beinse within Prof. Pierre Laurent-Puig’s team, through four scientific publications sharing a common goal: delivering the right treatment to the right patient at the right time.
Discover how two innovative approaches could transform the management of endometrial cancer:
🧬 A 38-gene RNA signature, designed to refine prognostic assessment and more accurately identify patients at risk of recurrence.
🩸 Liquid biopsy, which detects circulating tumor DNA (ctDNA) from a simple blood sample to monitor treatment response and anticipate disease recurrence.
These studies illustrate the ambition of translational research at SIRIC CARPEM: transforming scientific discoveries into practical tools that advance precision medicine for the benefit of patients.
Content generated with NotebookLM AI and reviewed by the CARPEM teams.
- Beinse G. Development and validation of a RNAseq signature for prognostic stratification in endometrial cancer. Gynecologic Oncology. 2022.
- Beinse G. Discovery and validation of a transcriptional signature identifying homologous recombination-deficient breast, endometrial and ovarian cancers. British Journal of Cancer. 2022.
- Beinse G. Highly Specific Droplet-Digital PCR Detection of Universally Methylated Circulating Tumor DNA in Endometrial Carcinoma. Clinical Chemistry. 2022.
- Beinse G. ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib. Clinical Cancer Research. 2026.